HK1139595A1 - 用於增强 細胞應答的方法 - Google Patents
用於增强 細胞應答的方法Info
- Publication number
- HK1139595A1 HK1139595A1 HK10105740.0A HK10105740A HK1139595A1 HK 1139595 A1 HK1139595 A1 HK 1139595A1 HK 10105740 A HK10105740 A HK 10105740A HK 1139595 A1 HK1139595 A1 HK 1139595A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cell response
- enhancing cell
- enhancing
- response
- cell
- Prior art date
Links
- 230000036755 cellular response Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90198007P | 2007-02-15 | 2007-02-15 | |
PCT/US2008/002044 WO2008100598A2 (en) | 2007-02-15 | 2008-02-15 | A method for enhancing t cell response |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1139595A1 true HK1139595A1 (zh) | 2010-09-24 |
Family
ID=39690701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10105740.0A HK1139595A1 (zh) | 2007-02-15 | 2010-06-09 | 用於增强 細胞應答的方法 |
HK10107835.2A HK1141251A1 (zh) | 2007-02-15 | 2010-08-17 | 用於增強 細胞應答的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10107835.2A HK1141251A1 (zh) | 2007-02-15 | 2010-08-17 | 用於增強 細胞應答的方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080199485A1 (zh) |
EP (2) | EP2129389B1 (zh) |
JP (2) | JP5755839B2 (zh) |
CN (2) | CN103736086A (zh) |
AU (1) | AU2008216669B2 (zh) |
CA (1) | CA2678353A1 (zh) |
ES (1) | ES2527412T3 (zh) |
HK (2) | HK1139595A1 (zh) |
MX (1) | MX2009008620A (zh) |
WO (1) | WO2008100598A2 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
JP5416968B2 (ja) * | 2005-06-17 | 2014-02-12 | マンカインド コーポレイション | 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物 |
WO2008121354A1 (en) | 2007-03-30 | 2008-10-09 | Duke University | A method of modulating the activity of a nucleic acid molecule |
WO2009155332A1 (en) | 2008-06-17 | 2009-12-23 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
DE102008061522A1 (de) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
WO2010075525A1 (en) * | 2008-12-24 | 2010-07-01 | Cedars-Sinai Medical Center | Method of using tumor cell debris to reduce brain tumor recurrence or growth |
US9468650B2 (en) | 2009-09-16 | 2016-10-18 | Duke University | Inhibition of endosomal toll-like receptor activation |
CA2778707A1 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
US20130108661A1 (en) | 2010-02-05 | 2013-05-02 | Mount Sinai School Of Medicine | Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
AU2013359907B2 (en) | 2012-12-11 | 2018-01-18 | Albert Einstein College Of Medicine, Inc. | Methods for high throughput receptor:ligand identification |
US20150037374A1 (en) * | 2013-07-31 | 2015-02-05 | Csl Limited | Anti-tumor compositions and uses thereof |
WO2015161094A1 (en) | 2014-04-16 | 2015-10-22 | Duke University | Electrospun cationic nanofibers and methods of making and using the same |
EP3265090A4 (en) | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating cancer associated with a ras mutation |
WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
US10568948B2 (en) | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
EP3334726B1 (en) | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
MY192703A (en) | 2016-02-08 | 2022-09-02 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
WO2017201131A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
EP3458096A4 (en) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE |
MX2018015100A (es) | 2016-06-06 | 2019-09-04 | Beyondspring Pharmaceuticals Inc | Composicion y metodo para reducir la neutropenia. |
IL297617B2 (en) | 2016-12-22 | 2023-11-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
US11733235B2 (en) | 2016-12-27 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating immunogenicity of test substance |
JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
WO2018144764A1 (en) | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
AU2018234628B2 (en) | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
EP3784688A2 (en) | 2018-04-26 | 2021-03-03 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
CN111135310B (zh) * | 2019-12-24 | 2021-05-07 | 江苏省人民医院(南京医科大学第一附属医院) | 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用 |
EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma Inc | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
CN116262779A (zh) * | 2021-12-14 | 2023-06-16 | 深圳先进技术研究院 | 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778879A (en) * | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
DE4143467C2 (de) * | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptidmotiv und dessen Verwendung |
US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
DE4423392A1 (de) | 1994-07-04 | 1996-01-11 | Birsner & Grob Biotech Gmbh | Verfahren zur Identifizierung antigener Peptide |
JPH10512155A (ja) | 1995-02-28 | 1998-11-24 | マックス−プランク−ゲゼルシャフト ツル フェルデルング デアヴイッセンシャフテン エー.ファウ.ベルリン | 癌およびその他の過形成を治療する薬剤 |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
WO1997047271A2 (en) * | 1996-06-12 | 1997-12-18 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
NZ502168A (en) | 1997-07-10 | 2002-08-28 | Ctl Immunotherapies Corp | Inducing and maintaining a CTL response by delivering antigen to the lymphatic system of a mammal via an external apparatus |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
AU749749B2 (en) * | 1998-03-16 | 2002-07-04 | Alk-Abello A/S | Mutant recombinant allergens |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20020165176A1 (en) * | 2000-05-01 | 2002-11-07 | Haynes Joel R. | Nucleic acid immunization |
GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
CN100589845C (zh) * | 2001-03-07 | 2010-02-17 | 麦康公司 | 用于治疗癌症的抗新血管系统制剂 |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
EP2314712B1 (en) | 2001-11-07 | 2014-01-08 | Mannkind Corporation | Expression vectors encoding epitopes of antigens and methods for their design |
NZ519363A (en) * | 2002-06-05 | 2004-02-27 | Agres Ltd | A novel drug dosing regimen |
JP2005537800A (ja) | 2002-09-06 | 2005-12-15 | マンカインド コーポレイション | エピトープ配列 |
AU2004249254B2 (en) | 2003-06-17 | 2010-07-08 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
ATE476196T1 (de) * | 2003-06-17 | 2010-08-15 | Mannkind Corp | Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke |
US6997074B2 (en) | 2003-10-30 | 2006-02-14 | Eaton Corporation | Prediction of destination gear for progressive shift feature |
US20050287068A1 (en) * | 2004-06-17 | 2005-12-29 | Bot Adrian I | Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
EP2332971B1 (en) * | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
US20060153844A1 (en) | 2004-12-29 | 2006-07-13 | Thomas Kundig | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
AU2005321905A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass CD+4 cells in the induction of an immune response |
US20060159694A1 (en) | 2004-12-29 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
CA2594224A1 (en) | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
EP1890724A2 (en) * | 2005-05-13 | 2008-02-27 | Oxxon Therapeutics Limited | Compositions for inducing an immune response |
-
2008
- 2008-02-15 MX MX2009008620A patent/MX2009008620A/es active IP Right Grant
- 2008-02-15 CN CN201410026166.0A patent/CN103736086A/zh active Pending
- 2008-02-15 CA CA002678353A patent/CA2678353A1/en not_active Abandoned
- 2008-02-15 WO PCT/US2008/002044 patent/WO2008100598A2/en active Application Filing
- 2008-02-15 EP EP08725654.1A patent/EP2129389B1/en not_active Not-in-force
- 2008-02-15 US US12/070,156 patent/US20080199485A1/en not_active Abandoned
- 2008-02-15 EP EP12165994A patent/EP2481418A1/en not_active Withdrawn
- 2008-02-15 ES ES08725654.1T patent/ES2527412T3/es active Active
- 2008-02-15 AU AU2008216669A patent/AU2008216669B2/en not_active Ceased
- 2008-02-15 JP JP2009549627A patent/JP5755839B2/ja not_active Expired - Fee Related
- 2008-02-15 CN CN200880012207.3A patent/CN101657213B/zh not_active Expired - Fee Related
-
2010
- 2010-06-09 HK HK10105740.0A patent/HK1139595A1/zh not_active IP Right Cessation
- 2010-08-17 HK HK10107835.2A patent/HK1141251A1/zh not_active IP Right Cessation
-
2013
- 2013-11-25 JP JP2013242826A patent/JP2014043459A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101657213A (zh) | 2010-02-24 |
EP2129389B1 (en) | 2014-10-08 |
JP2014043459A (ja) | 2014-03-13 |
EP2129389A2 (en) | 2009-12-09 |
AU2008216669B2 (en) | 2013-12-12 |
AU2008216669A1 (en) | 2008-08-21 |
MX2009008620A (es) | 2009-10-22 |
CN101657213B (zh) | 2014-02-26 |
CA2678353A1 (en) | 2008-08-21 |
HK1141251A1 (zh) | 2010-11-05 |
CN103736086A (zh) | 2014-04-23 |
JP2010519205A (ja) | 2010-06-03 |
WO2008100598A2 (en) | 2008-08-21 |
ES2527412T3 (es) | 2015-01-23 |
WO2008100598A3 (en) | 2008-12-31 |
EP2481418A1 (en) | 2012-08-01 |
JP5755839B2 (ja) | 2015-07-29 |
US20080199485A1 (en) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1141251A1 (zh) | 用於增強 細胞應答的方法 | |
ZA201001753B (en) | Method for consumer-dispenser interactions | |
GB0707096D0 (en) | Method | |
EP2171169A4 (en) | METHOD | |
GB0714442D0 (en) | Method | |
AP2937A (en) | Method for counting cells | |
EP2170479A4 (en) | RECOVERY PROCESS | |
ZA200908352B (en) | Method for cell separation | |
EP2118273A4 (en) | METHOD OF MODIFYING CELLS | |
GB0810558D0 (en) | Method for cell manipulation | |
GB0703366D0 (en) | Method | |
GB0724491D0 (en) | A method | |
GB0709803D0 (en) | Predictive method | |
GB0710321D0 (en) | Method | |
GB0708960D0 (en) | Method | |
EP2220489A4 (en) | METHOD FOR PREDICTING RESPONSE TO THERAPY | |
GB0705321D0 (en) | Method | |
GB0710519D0 (en) | Method | |
EP2342055A4 (en) | METHOD FOR ASSEMBLING A STRUCTURE | |
GB0714135D0 (en) | Method | |
GB0710520D0 (en) | Method | |
GB0706833D0 (en) | Method | |
GB0710518D0 (en) | Method | |
GB0710398D0 (en) | Method | |
TWI339916B (en) | Method for making a battery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190215 |